Basics Vericel Corporation Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company. The company operates in one reportable segment: the research, manufacture, and distribution of patient-specific, used in the treatment of specific diseases. IPO Date: November 25, 2014 Sector: Healthcare Industry: Biotech Market Cap: $1.72B Activated in VL: True Average Daily Range Avg Daily Range: $0.56 | 2.54% Avg Daily Range (30 D): $0.78 | 2.11% Avg Daily Range (90 D): $0.82 | 2.07% Institutional Daily Volume Avg Daily Volume: .45M Avg Daily Volume (30 D): .51M Avg Daily Volume (90 D): .45M Trade Size Avg Trade Size (Sh.): 99 Avg Trade Size (Sh.) (30 D): 50 Avg Trade Size (Sh.) (90 D): 47 Institutional Trades Total Inst.Trades: 2,838 Avg Inst. Trade: $2.5M Avg Inst. Trade (30 D): $2.24M Avg Inst. Trade (90 D): $2.34M Avg Inst. Trade Volume: .08M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.94M Avg Closing Trade (30 D): $2.67M Avg Closing Trade (90 D): $3.19M Avg Closing Volume: 89.39K     News Aug 14, 2025 @ 6:22 PM MediWound Revenue Jumps 43% in Q2 Source: Na Aug 5, 2025 @ 7:14 PM Vericel Q2 Revenue Jumps 20% Source: Jesterai Aug 1, 2024 @ 11:55 AM Vericel Reports Second Quarter 2024 Financial Resu... Source: Vericel Corporation Jul 30, 2024 @ 6:00 AM Global Regenerative Medicine Market Size To Worth ... Source: Spherical Insights & Consulting Jul 18, 2024 @ 9:02 PM Vericel corp chief legal officer sells $782,700 in... Source: Investing.Com Financials   TTM Q2 2025 Q1 2025 Basic EPS $.14 $-.01 $-.23 Diluted EPS $.13 $-.01 $-.23 Revenue $ 249.12M $ 63.24M $ 52.6M Gross Profit $ 183.04M $ 46.61M $ 36.27M Net Income / Loss $ 7.11M $ -.55M $ -11.25M Operating Income / Loss $ 1.19M $ -2.03M $ -12.79M Cost of Revenue $ 66.08M $ 16.63M $ 16.33M Net Cash Flow $ 4.68M $ .83M $ -5.34M PE Ratio 261.92     Splits Oct 16, 2013:   1:20 Feb 18, 2010:   1:8